Allergy Technologies LLC, manufacturer of ActiveGuard™ Mattress Liners, is funding a second year of bed bug research at The Ohio State University with an additional $100,000+ grant. This grant is an extension of last year’s support by the Company that enabled the launch of this essential research initiative.
Extension of this programmatic grant to The Ohio State University will allow for the continued support of a variety of research investigations relating to bed bugs, including various product efficacy, treatment protocols, and application methods to control bed bugs. Given the continued rise in bed bug infestations and the growing cost of treatments throughout the country, Allergy Technologies' continued sponsorship will allow for much needed field and lab research integral to the development of promising bed bug products and strategies. Given the impact of the bed bug scourge that is sweeping the nation, the results of this research may have direct influence on treatment and preventative strategies for residences, colleges and universities, and hotels.
“Allergy Technologies’ funding of this research allows us to continue and complete some very valuable studies and trials relating to bed bug behavior, control strategies, resistance, repellency and more,” said Dr. Susan Jones, principal investigator on the project. As part of the 2nd year of the grant, Susan Jones, PhD and her team of urban entomologists will continue to examine behavioral and feeding characteristics of bed bugs, including their response to existing and novel products related to bed bug management.
According to Dr. Jones, “the core rationale of this research is to improve pest management practices and protocols relating to the proper control of bed bugs. Year Two funding gives us the opportunity to apply the results from the important laboratory studies we completed in the first year and transition into field studies while continuing to expand our fundamental behavioral research.”
Gus Carey, Managing Director and CEO of Allergy Technologies acknowledged the strong affiliation that his company has with Dr. Jones and The Ohio State team. “We have been continuously impressed with the knowledge and dedication of Susan Jones and her group of urban entomologists. Dr. Jones’ strong understanding of bed bugs and their habits was one of the key reasons for working with Ohio State in the first place. Her work over the past year has greatly enhanced our understanding how bed bugs behave in the field and we look forward to continuing that research to help us find working solutions to eliminate these pests.”
“Bed bug infestations have dramatically increased over the course of the last decade, making this research so much more valuable to the pest control community,” said Joseph Latino, Chief Operating Officer (COO) for Allergy Technologies. “This grant directly underscores Allergy Technologies’ principal business paradigm of continuing our focus on supporting both the pest control industry and inner-city communities through our Philanprofit™ efforts.”
ActiveGuard by Allergy Technologies LLC, are thin and breathable liners easily installed onto mattresses and box springs, which kill bed bugs and dust mites continuously for up to two years.
Allergy Technologies and a team of research entomologists originally developed ActiveGuard for use against house dust mites. Distinct from encasements, ActiveGuard has been extensively lab and field tested for use in both active and preventative bed bug control strategies.
About Allergy Technologies
Allergy Technologies is a subsidiary of A. Carey Co. LLC, which focuses on using philanthropy as a core business strategy for its businesses. Through its Philanprofit strategy, a portion of all ActiveGuard proceeds go to help fund inner-city homeless and women’s shelters and asthma clinics.
For more information, call (866) 978-6288 or visit www.allergytechnologies.com.
Media Contact:
Ed DeMask
DeMask Marketing
630-768-1404, cell
630-389-0572, office
ed@demaskmarketing.com
